Home Health Italy authorizes study of heparin use in patients with COVID-19

Italy authorizes study of heparin use in patients with COVID-19

Italy authorizes a study of heparin use in patients with COVID-19: Recently it was disclosed that the Italian Medicines Agency (AIFA) authorized to initiate a multicenter study with the drug heparin, which mainly works as a low molecular weight anticoagulant, for the treatment of patients with a moderate or severe clinical picture of COVID coronavirus. COVID-19.

Italy authorizes a study of heparin

This study seeks to evaluate the safety and efficacy of this drug, which will be administered in different doses, to improve the course of the disease.

The medication is provided free of charge to 14 Italian centers participating in the study, involving a total of 300 patients, who will receive enoxaparin biosimilar for subcutaneous injection.

What is enoxaparin?

The enoxaparin sodium is low molecular weight heparin with high action antithrombotic that makes today, one of the anticoagulants most used for prevention and therapy of the venous and arterial thrombosis in patients undergoing surgery or bedridden.

The study will be coordinated by Pierluigi Viale, Professor of Infectious Diseases of the University of Bologna and Director of the Operational Infectious Disease Unit of the Hospital Sant’Orsola-Malpighi.

The experts point out that alterations of coagulation and thrombotic complications in patients coronavirus Covid-19 play an important role in terms of incidence and clinical relevance, representing one of the most important variables associated with mortality from this disease.

Is the WHO recommend heparin?

In January, the World Health Organization (WHO) recommended preventing venous thromboembolism in subjects infected with SARS-CoV-2 by resorting to subcutaneous administration of heparin, preferably with low molecular weight.

This idea gave rise to an experiment also in Italy through the use, for therapeutic purposes, of a medium-high dose of medication.

We thank AIFA for this speedy approval, which will allow the centers involved to begin work to demonstrate the justification for this scientific hypothesis. We need to obtain evidence quickly, and therefore we must work in clinical trials, associating our intuitions and hopes with the necessary methodological rigor ”, commented Dr. Viale.

Load More Related Articles
Load More In Health

Check Also

Medical Conditions that can Benefit from the Use of Medical Marijuana

Maryland is part of the Mid-Atlantic US and has many waterways and coastlines that span fr…